Mesoblast (NASDAQ:MESO) Downgraded to “Hold” Rating by Jefferies Financial Group

Mesoblast (NASDAQ:MESO) was downgraded by investment analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday, MarketBeat Ratings reports.

MESO has been the subject of a number of other reports. Maxim Group raised Mesoblast from a “hold” rating to a “buy” rating and set a $12.00 price target for the company in a research report on Tuesday, September 24th. Piper Sandler raised their target price on Mesoblast from $11.00 to $15.00 and gave the company an “overweight” rating in a research report on Thursday. StockNews.com downgraded shares of Mesoblast from a “hold” rating to a “sell” rating in a report on Wednesday, September 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Mesoblast in a research report on Thursday, August 29th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $13.50.

Mesoblast Stock Performance

NASDAQ:MESO opened at $14.63 on Monday. Mesoblast has a 52 week low of $1.61 and a 52 week high of $19.15. The firm has a 50-day moving average price of $10.48 and a two-hundred day moving average price of $8.29. The company has a current ratio of 1.18, a quick ratio of 1.18 and a debt-to-equity ratio of 0.21.

Institutional Investors Weigh In On Mesoblast

Institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new stake in shares of Mesoblast in the second quarter valued at approximately $562,000. Signaturefd LLC lifted its holdings in Mesoblast by 128.7% during the 3rd quarter. Signaturefd LLC now owns 5,506 shares of the company’s stock worth $45,000 after purchasing an additional 3,099 shares in the last quarter. Rathbones Group PLC purchased a new position in Mesoblast during the 2nd quarter valued at about $95,000. Creative Planning bought a new stake in shares of Mesoblast during the third quarter valued at about $147,000. Finally, Perkins Coie Trust Co boosted its position in shares of Mesoblast by 15.0% in the third quarter. Perkins Coie Trust Co now owns 11,500 shares of the company’s stock valued at $94,000 after acquiring an additional 1,500 shares during the period. 1.43% of the stock is owned by hedge funds and other institutional investors.

About Mesoblast

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.